Trevi Therapeutics
IPO News: Filed S-1: Trevi Therapeutics Files $86.3mm IPO
Trevi Therapeutics

Trevi Therapeutics

NASDAQ:  TRVI

Size (mm):  $86.3

Bookrunners:  LEER | STFL | BMO

Major Holders: TPG Biotechnology Partners | New Enterprise Associates | Lundbeckfond Invest | Omega Fund

Description:  Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions

Note: Emerging Growth Company

Reference Link: S-1